Figure 1.
Figure 1. Sites of action for oral anticoagulants approved for stroke prevention in AF. Idarucizumab, andexanet,* and ciraparantag* are specific reversal agents for the NOAC.7,33,66 *Not currently approved for clinical use.

Sites of action for oral anticoagulants approved for stroke prevention in AF. Idarucizumab, andexanet,* and ciraparantag* are specific reversal agents for the NOAC.7,33,66  *Not currently approved for clinical use.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal